Covert dose reduction is a distinct type of medication non-adherence observed across all care settings in Inflammatory Bowel Disease

Journal of Crohn's and Colitis

Volumn 8, Issue 12, 2014, Pages 1723-1729

  Mountifield, Réme ^a,c   Andrews, Jane M ^b,c   Mikocka Walus, Antonina ^d   Bampton, Peter ^a,c  

^a FLINDERS MEDICAL CENTRE   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c FLINDERS UNIVERSITY   (Australia)

^d UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

Complementary and Alternative Medicine; Dose modification; ; Inflammatory Bowel Disease; Medication adherence; Medication attitudes

Indexed keywords

ANTIINFLAMMATORY AGENT; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT;

ALTERNATIVE MEDICINE; ANXIETY; ATTITUDE TO HEALTH; AUSTRALIA; CROSS-SECTIONAL STUDY; DEPRESSION; DOCTOR PATIENT RELATION; EPIDEMIOLOGY; FEMALE; HUMAN; INFLAMMATORY BOWEL DISEASES; MALE; MEDICATION COMPLIANCE; MIDDLE AGED; PSYCHOLOGY; QUESTIONNAIRE; UTILIZATION;

ANTI-INFLAMMATORY AGENTS; ANXIETY; ATTITUDE TO HEALTH; AUSTRALIA; COMPLEMENTARY THERAPIES; CROSS-SECTIONAL STUDIES; DEPRESSION; FEMALE; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PHYSICIAN-PATIENT RELATIONS; QUESTIONNAIRES;

EID: 84918526003     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2014.08.013     Document Type: Article

References (43)

1. Higgins P.D., Rubin D.T., Kaulback K., Schoenfield P.S., Kane S.V. Systematic review: impact of non-adherence to 5-aminosalicylic acid products on the frequency and cost of ulcerative colitis flares. Aliment Pharmacol Ther Feb 1 2009, 29(3):247-257.
2. Chapman C.G., Rubin D.T. The potential for medical therapy to reduce the risk of colorectal cancer and optimize surveillance in inflammatory bowel disease. Gastrointest Endosc Clin N Am Jul 2014, 24(3):353-365.
3. Biancone L., Michetti P., Travis S., Escher J.C., Moser G., Forbes A., et al. European evidence-based Consensus on the management of ulcerative colitis: special situations. J Crohns Colitis Mar 2008, 2(1):63-92.
4. Jackson C.A., Clatworthy J., Robinson A., Horne R. Factors associated with non-adherence to oral medication for inflammatory bowel disease: a systematic review. Am J Gastroenterol Mar 2010, 105(3):525-539.
5. Ediger J.P., Walker J.R., Graff L., Lix L., Clara I., Rawsthorne P., et al. Predictors of medication adherence in inflammatory bowel disease. Am J Gastroenterol Jul 2007, 102(7):1417-1426.
6. Kane S.V., Cohen R.D., Aikens J.E., Hanauer S.B. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol Oct 2001, 96(10):2929-2933.
7. Mantzaris G.J., Roussos A., Kalantzis C., Koilakou S., Raptis N., Kalantzis N. How adherent to treatment with azathioprine are patients with Crohn's disease in long-term remission?. Inflamm Bowel Dis Apr 2007, 13(4):446-450.
8. Lakatos P.L., Czegledi Z., David G., Kispal Z., Kiss L.S., Palatka K., et al. Association of adherence to therapy and complementary and alternative medicine use with demographic factors and disease phenotype in patients with inflammatory bowel disease. J Crohns Colitis Sep 2010, 4(3):283-290.
9. Horne R., Parham R., Driscoll R., Robinson A. Patients' attitudes to medicines and adherence to maintenance treatment in inflammatory bowel disease. Inflamm Bowel Dis Jun 2009, 15(6):837-844.
10. Selinger C.P., Eaden J., Jones D.B., Katelaris P., Chapman G., McDonald C., et al. Modifiable factors associated with nonadherence to maintenance medication for inflammatory bowel disease. Inflamm Bowel Dis Sep 2013, 19(10):2199-2206.
11. Lopez San Roman A., Bermejo F., Carrera E., Perez-Abad M., Boixeda D. Adherence to treatment in inflammatory bowel disease. Rev Esp Enferm Dig Apr 2005, 97(4):249-257.
12. Van Langenberg D.R., AJ Satisfaction with patient-doctor relationships in inflammatory bowel diseases: examining patient initiated change of specialist. World J Gastroenterol 2012, 18(18):2212-2218.
13. López San Román A., Bermejo F., Carrera E., Pérez-Abad M., Boixeda D. Adherence to treatment in inflammatory bowel disease. Rev Esp Enferm Dig 2005, 97:249-257.
14. Linn A.J., van Dijk L., Smit E.G., Jansen J., van Weert J.C. May you never forget what is worth remembering: the relation between recall of medical information and medication adherence in patients with inflammatory bowel disease. J Crohns Colitis 2013, 7(11):e543-e550.
15. Nigro G., Angelini G., Grosso S.B., Caula G., Sategna-Guidetti C. Psychiatric predictors of noncompliance in inflammatory bowel disease: psychiatry and compliance. J Clin Gastroenterol Jan 2001, 32(1):66-68.
16. Sewitch M.J., Abrahamowicz M., Barkun A., Bitton A., Wild G.E., Cohen A., et al. Patient nonadherence to medication in inflammatory bowel disease. Am J Gastroenterol Jul 2003, 98(7):1535-1544.
17. Shale M.J., Riley S.A. Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2003, 18(2):191-198.
18. Lee K., Mokhtar H.H., Krauss S.E., Ong B.K. Hypertensive patients' preferences for complementary and alternative medicine and the influence of these preferences on the adherence to prescribed medication. Complement Ther Clin Pract May 2014, 20(2):99-105.
19. Vrijens B., Urquhart J. Methods for measuring, enhancing, and accounting for medication adherence in clinical trials. Clin Pharmacol Ther Jun 2014, 95(6):617-626.
20. Robinson A. Review article: improving adherence to medication in patients with inflammatory bowel disease. Aliment Pharmacol Ther Mar 2008, 27(Suppl. 1):9-14.
21. Morisky D.E., Green L.W., Levine D.M. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care Jan 1986, 24(1):67-74.
22. Morisky D.E., Ang A., Krousel-Wood M., Ward H.J. Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens May 2008, 10(5):348-354.
23. Kim E., Gupta S., Bolge S., Chen C.C., Whitehead R., Bates J.A. Adherence and outcomes associated with copayment burden in schizophrenia: a cross-sectional survey. J Med Econ 2010, 13(2):185-192.
24. Zigmond A.S., Snaith R.P. The hospital anxiety and depression scale. Acta Psychiatr Scand Jun 1983, 67(6):361-370.
25. Irvine E.J., Zhou Q., Thompson A.K. The Short Inflammatory Bowel Disease Questionnaire: a quality of life instrument for community physicians managing inflammatory bowel disease. CCRPT Investigators. Canadian Crohn's Relapse Prevention Trial. Am J Gastroenterol Aug 1996, 91(8):1571-1578.
26. Spielberger C.D. Cross-cultural assessment of emotional states and personality traits. Eur Psychol 2006, 11(4):297-303.
27. Spielberger C. Manual for the State Trait Personality Inventory 1970, Consulting Psychologist Press, Palo Alto CA.
28. Forsberg C., Bjorvell H. Swedish population norms for the GHRI, HI and STAI-state. Qual Life Res Int J Qual Life Asp Treat Care Rehab Oct 1993, 2(5):349-356.
29. Panara A.J., Yarur A.J., Rieders B., Proksell S., Deshpande A.R., Abreu M.T., et al. The incidence and risk factors for developing depression after being diagnosed with inflammatory bowel disease: a cohort study. Aliment Pharmacol Ther Apr 2014, 39(8):802-810.
30. Jaeger S., Pfiffner C., Weiser P., et al. Adherence styles of schizophrenia patients identified by a latent class analysis of the Medication Adherence Rating Scale (MARS): a six-month follow-up study. Psychiatry Res 2012, 200(2-3):83-88.
31. Yen L., Wu J., Hodgkins P.L., Cohen R.D., Nichol M.B. Medication use patterns and predictors of nonpersistence and nonadherence with oral 5-aminosalicylic acid therapy in patients with ulcerative colitis. J Manag Care Pharm Nov-Dec 2012, 18(9):701-712.
32. Cerveny P., Bortlik M., Kubena A., Vlcek J., Lakatos P.L., Lukas M. Nonadherence in inflammatory bowel disease: results of factor analysis. Inflamm Bowel Dis Oct 2007, 13(10):1244-1249.
33. D'Inca R., Bertomoro P., Mazzocco K., Vettorato M.G., Rumiati R., Sturniolo G.C. Risk factors for non-adherence to medication in inflammatory bowel disease patients. Aliment Pharmacol Ther 2008, 27(2):166-172.
34. Bokemeyer B., Teml A., Roggel C., Hartmann P., Fischer C., Schaeffeler E., et al. Adherence to thiopurine treatment in out-patients with Crohn's disease. Aliment Pharmacol Ther 2007, 26(2):217-225.
35. Horne R., Chapman S.C., Parham R., Freemantle N., Forbes A., Cooper V. Understanding patients' adherence-related beliefs about medicines prescribed for long-term conditions: a meta-analytic review of the Necessity-Concerns Framework. PLoS One 2013, 8(12):e80633.
36. Goodhand J.R., Kamperidis N., Sirwan B., Macken L., Tshuma N., Koodun Y., et al. Factors associated with thiopurine non-adherence in patients with inflammatory bowel disease. Aliment Pharmacol Ther Nov 2013, 38(9):1097-1108.
37. Long M.D., Kappelman M.D., Martin C.F., Chen W., Anton K., Sandler R.S. Risk factors for depression in the elderly inflammatory bowel disease population. J Crohns Colitis Feb 2014, 8(2):113-119.
38. McCombie A.M., Mulder R.T., Gearry R.B. Psychotherapy for inflammatory bowel disease: a review and update. J Crohns Colitis 2013, 7(12):935-949.
39. Nahon S., Lahmek P., Durance C., Olympie A., Lesgourgues B., Colombel J.F., et al. Risk factors of anxiety and depression in inflammatory bowel disease. Inflamm Bowel Dis Nov 2012, 18(11):2086-2091.
40. Gray W.N., Denson L.A., Baldassano R.N., Hommel K.A. Treatment adherence in adolescents with inflammatory bowel disease: the collective impact of barriers to adherence and anxiety/depressive symptoms. J Pediatr Psychol Apr 2012, 37(3):282-291.
41. Nahon S., Lahmek P., Saas C., Durance C., Olympie A., Lesgourgues B., et al. Socioeconomic and psychological factors associated with nonadherence to treatment in inflammatory bowel disease patients: results of the ISSEO survey. Inflamm Bowel Dis Jun 2011, 17(6):1270-1276.
42. Weizman A.V., Ahn E., Thanabalan R., Leung W., Croitoru K., Silverberg M.S., et al. Characterisation of complementary and alternative medicine use and its impact on medication adherence in inflammatory bowel disease. Aliment Pharmacol Ther Feb 2012, 35(3):342-349.
43. Nousiainen P., Merras-Salmio L., Aalto K., Kolho K.L. Complementary and alternative medicine use in adolescents with inflammatory bowel disease and juvenile idiopathic arthritis. BMC Complement Altern Med 2014, 14(1):124.